Hutchison MediPharma International

HUTCHMED is a global biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases. The company has built a robust internal R&D engine that has produced a deep pipeline of small molecule drug candidates, with three products—Fruzaqla, Sulanda, and Orpathys—already approved and marketed in China. Fruzaqla (fruquintinib) has also achieved significant international success, receiving FDA approval for metastatic colorectal cancer. HUTCHMED operates with a fully integrated platform, including R&D, manufacturing, and a large-scale commercial organization. Strategic collaborations with global leaders such as AstraZeneca and Takeda further support the company's mission to bring innovative treatments to patients worldwide.